Related Experiment Video

Updated: Jun 10, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical

M Aboud1, A Elgalib, L Pomeroy

  • 1HIV Medicine, Guy's & St Thomas' Hospitals, London, UK.

International Journal of Clinical Practice
|July 27, 2010
PubMed

Insights

This study reveals that modifiable factors like cholesterol and highly active antiretroviral therapy (HAART) duration significantly impact cardiovascular disease (CVD) risk in HIV patients. Regular risk assessments are crucial, especially during HAART.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Public Health

Background:

  • HIV infection is associated with an increased risk of cardiovascular disease (CVD).
  • Highly active antiretroviral therapy (HAART) has transformed HIV management but may influence CVD risk.
  • Understanding the CVD risk profile in HIV patients on HAART is crucial for preventative strategies.

Purpose of the Study:

  • To determine the cardiovascular disease (CVD) risk profile of a large UK HIV cohort.
  • To investigate the impact of highly active antiretroviral therapy (HAART) on CVD risk in this population.

Main Methods:

  • A cross-sectional study involving 1021 HIV-positive outpatients.
  • Demographics, HAART history, and CVD risk factors were recorded.
  • Cardiovascular disease (CVD) and coronary heart disease (CHD) risks were calculated using the Framingham (1991) algorithm.

Main Results:

  • Elevated cholesterol was a primary risk factor for CVD.
  • Increased coronary heart disease (CHD) risk was strongly linked to the duration of HAART.
  • CVD risk was higher in Caucasian patients compared to other ethnicities.

Conclusions:

  • Modifiable risk factors, particularly cholesterol levels and HAART duration, are key determinants of CVD risk in HIV patients.
  • Regular CVD and CHD risk assessment is recommended for all HIV patients, especially those on HAART.
  • Consideration of HAART regimens' effects on CHD risk is vital during treatment selection.
Abstract

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...